arrow
S

Stefan N. Symeonides

University of Edinburgh
H指数:25
被引数:3,737
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study

辅助治疗用帕博利珠单抗治疗透明细胞肾细胞癌:KEYNOTE-564 III期研究五年结果

2026-08-260
PRE
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

RO7300490的安全性及活性评估:一种靶向纤维细胞活化蛋白的双特异性CD40激动剂,用于晚期实体瘤患者的单臂、多中心、首次人体、Ⅰ期临床试验

2026-05-010
PRE
A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR)

早期剂量探索性肿瘤临床试验中患者报告结局的分析与可视化实用工具包与建议(OPTIMISE-AR)

2026-03-170
PRE
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology

Experimental Cancer Medicine Centre (ECMC)网络关于泛癌种测序的共识基因面板的提案:一种德尔菲方法

2025-11-080
OAAI
Leveraging knowledge for explainable AI in personalized cancer treatment: challenges and future directions

利用知识实现可解释性人工智能在个性化癌症治疗中的应用:挑战与未来方向

2025-09-290
OAAI
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

德法替尼联合阿瓦替尼治疗实体瘤患者: 1期框架试验

2025-06-270
OAAI
Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment

Fibroblast activation protein (FAP)-CD40 (RO7300490) 介导肿瘤内树突状细胞成熟及肿瘤微环境的调控

2024-09-010
PRE
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

辅助Pembrolizumab治疗肾细胞癌的总生存率

2024-04-1840
PRE
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
2023-03-027
OAAI